Table 2.

Scope of CINV

QUESTION	All Healthcare Providers, %	Hematology/Oncology Physicians, %	Hematology/Oncology Nurses, %	P Value*
Of your patients who experienced chemotherapy-induced nausea and vomiting (CINV) last year, what type of CINV was most common? (Select all that apply)
Anticipatory nausea/vomiting	31	27	31	.18
Breakthrough nausea/vomiting	50	78	84	.03
Refractory nausea/vomiting	19	16	22	.08
Of your patients who experienced CINV last year, which was the most problematic to manage?
Acute nausea	27	9	20	<.0001
Acute vomiting	23	8	11	.55
Delayed nausea	33	61	50	.06
Delayed vomiting	17	21	20	.88
Please indicate the degree to which you agree with the statement. (Strongly Agree/Agree)
Chemotherapy-induced nausea and vomiting are well controlled in my patients.	81	95	88	.01
In the past year, I've had to delay or discontinue a patient's chemotherapy due to CINV.	45	31	32	.92
What are barriers to optimal management of CINV in your institution? (Select all that apply)
Cost	48	59	47	.13
Improper treatment selection	23	19	19	.86
Ineffective therapies	25	17	23	.34
Limited options on formulary	31	24	26	1.00
Nonadherence to guidelines	23	32	22	.08
Not understanding patient-related factors that affect CINV risk	32	25	28	.66
Not understanding emetogenic risk of cancer therapy	14	10	10	.92
Patient noncompliance	38	37	48	.04
Poor patient-clinician communication	30	21	29	.08
Other	6	3	7	.15
What is your preferred method of administration of CINV therapy?
IV	47	43	60	.002
Oral	31	40	34	.36
Transdermal	12	10	3	.002
Subcutaneous	5	6	2	.03
Other	4	1	2	.25
Why is this administration preferred? (Select all that apply)
Convenience for physician	16	30	11	<.0001
Convenience for patient	70	67	71	1.00
Ensures patient compliance	37	47	43	.49
Most efficacious	36	41	42	.29
Prevents multiday administration	15	22	14	.14
Side effect profile	12	12	11	.35
Reimbursement/cost	14	16	25	.06
Other	6	1	7	.002

^*Comparisons were between hematology/oncology physicians and hematology/oncology nurses.